Company intelligence / Profile preview

SEED Therapeutics

New York, New York, United Statesseedtherapeutics.com ↗

Ownership: Private
Employees: ~17
Development stage: Other

Overview

SEED Therapeutics has achieved multiple milestones in its research collaborations, including a 3rd milestone with Lilly R&D in March 2024 and a strategic research collaboration with Eisai in August 2024. The company plans to advance its oral RBM39 Degrader into Phase 1 testing in 2025 and progress its Tau degrader program for Alzheimer's disease into in vivo efficacy in 2025, with IND planned for 2026.

Therapeutic areas: OncologyNeurologyInfectious Diseases
Modalities: Molecular GluesTargeted Protein Degradation (TPD)
Industry: Biotech

Drug pipeline

4 assets

GST101

3 more assets in the full pipeline.

Partnerships

Eli Lilly and CompanyEisai Co., Ltd.

Beyond the preview

Go deeper on SEED Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SEED Therapeutics.